Secukinumab for the Inflammatory Phase of Pyoderma Gangrenosum

NCT04274166 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Contracting never completed, closed the IRB

Conditions

Pyoderma Gangrenosum

Interventions

DRUG: secukinumab 150 mg (2 injections per dose

Sponsor

Wake Forest University Health Sciences

Collaborators

[object Object]